

# Stanford

---



## James Kahn

Professor of Medicine (General Medical Disciplines), Emeritus  
Medicine - Primary Care and Population Health

 NIH Biosketch available Online

 Curriculum Vitae available Online

### Bio

---

#### ACADEMIC APPOINTMENTS

- Emeritus Faculty - University Medical Line, Medicine - Primary Care and Population Health

#### ADMINISTRATIVE APPOINTMENTS

- Director, Trainee Experience, VAPAHCS, (2016-2022)
- Chief of the Medical Service, VA Palo Alto Health Care System, (2012-2016)

#### HONORS AND AWARDS

- AOA, University of California, San Francisco
- Gold Headed Cane Society, University of California, San Francisco (1982)
- Charles C. Shepard Science Award for Scientific Excellence, Centers for Disease Control and Prevention (1999)
- Outstanding Mentor, University of California, San Francisco, AIDS Research Institute (2008)
- Chief Resident's Award for Outstanding Contribution to Resident Education, Stanford University Department of Medicine (2018)
- Visiting Professor, VA Boston Health Care System (March, 2019)
- Chief Resident's Award for Outstanding Contribution to Resident Education, Stanford University (2021)

#### PROFESSIONAL EDUCATION

- AB, University of California, Berkeley , American History (1978)
- MD, University of California, San Francisco , Medicine (1982)
- Intern, Johns Hopkins Hospital--Osler Service , Medicine (1983)
- Resident, Johns Hopkins Hospital--Osler Service , Medicine (1984)
- Resident, University of California, San Francisco , Medicine, Primary Care (1985)
- Fellow, University of California, San Francisco , Medical Oncology (1987)

### Research & Scholarship

---

#### CURRENT RESEARCH AND SCHOLARLY INTERESTS

My initial research activities have focused on three areas: antiretroviral and novel therapeutic treatments of HIV infection, understanding elements of HIV pathogenesis associated with acute HIV infection and post exposure prevention. My most recent scholarly activities concentrate on working as a team to capitalize on the data stored in electronic medical records, HIV disease modeling and using electronic medical records for outcome research and developing a mentorship program for doctoral, post-doctoral scholars and early career faculty dedicated to translational and clinical research. I have experience as the national chair for an NIAID sponsored AIDS

Clinical Trials Group study and I have conducted Phase 1 through Phase 3 studies. My scholarship has been supported by funding from the NIH for 24 years through a variety of mechanisms including, as the principal investigator of R01, R18, R24, R35 and K24 grants and co-investigator for R01, R18, R24 and R33 awards. Three foundations have supported my scholarly activities: the California Healthcare Foundation, the Blue Shield Foundation and the Commonwealth Foundation and I have received three career awards, one from the American Cancer Society and two K24 awards from the NIH (NIMH and NCRR).

## Teaching

---

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

## Publications

---

### PUBLICATIONS

- **Modeling UNAIDS treatment targets for China.** *AIDS (London, England)*

Blower, S., Okano, J. T., Kahn, J. S.  
2023; 37 (7): 1175-1176

- **Alone, lonely, and missed.** *The Lancet. Respiratory medicine*

Kahn, J. n.  
2021

- **The changing HIV epidemic: a view from the front line in the United States.** *AIDS (London, England)*

Kahn, J.  
2020; 34 (10): 1437–38

- **I'm Sorry.** *JAMA*

Kahn, J. S.  
2020; 323 (17): 1692–93

- **Nesting at the End of Life.** *Journal of palliative medicine*

Kahn, J. S.  
2019; 22 (12): 1617–18

- **Walking Home** *JAMA NEUROLOGY*

Kahn, J. S.  
2019; 76 (2): 138–39

- **What Can I Do as a Physician to Prevent Firearm Injury?** *ANNALS OF INTERNAL MEDICINE*

Kahn, J. S.  
2018; 169 (10): 725–26

- **Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial.** *JAMA oncology*

Patel, M. I., Sundaram, V., Desai, M., Periyakoil, V. S., Kahn, J. S., Bhattacharya, J., Asch, S. M., Milstein, A., Bundorf, M. K.  
2018

- **A Difficult Patient** *Annals of Internal Medicine*

Kahn, J. S.  
2018; 168 (11): 830-1

- **Despite My Best Intentions.** *JAMA*

Kahn, J. S.  
2017; 318 (17): 1653-1654

- **Effect of an Intensive Outpatient Program to Augment Primary Care for High-Need Veterans Affairs Patients: A Randomized Clinical Trial.** *JAMA internal medicine*

Zulman, D. M., Pal Chee, C., Ezeji-Okoye, S. C., Shaw, J. G., Holmes, T. H., Kahn, J. S., Asch, S. M.

2017; 177 (2): 166-175

- **A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction** *ADVANCES IN MEDICAL EDUCATION AND PRACTICE*  
Kahn, J. S., Witteles, R. M., Mahaffey, K. W., Desai, S. A., Ozdalga, E., Heidenreich, P. A.  
2017; 8: 559–66
- **Acceptance of Advance Directives and Palliative Care Referral for Veterans With Advanced Cancer: A Retrospective Analysis.** *The American journal of hospice & palliative care*  
Patel, M. I., Bhattacharya, J., Asch, S. M., Kahn, J.  
2016; 33 (8): 742-747
- **See One, Do One, Teach One, But Practice First.** *Journal of palliative medicine*  
Kahn, J. n.  
2016; 19 (6): 675–76
- **Partnered Research in Healthcare Delivery Redesign for High-Need, High-Cost Patients: Development and Feasibility of an Intensive Management Patient-Aligned Care Team (ImPACT)** *JOURNAL OF GENERAL INTERNAL MEDICINE*  
Zulman, D. M., Ezeji-Okoye, S. C., Shaw, J. G., Hummel, D. L., Holloway, K. S., Smither, S. F., Breland, J. Y., Chardos, J. F., Kirsh, S., Kahn, J. S., Asch, S. M.  
2014; 29: S861-S869
- **Development and Implementation of a Workshop to Enhance the Effectiveness of Mentors Working with Diverse Mentees in HIV Research** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Gandhi, M., Fernandez, A., Stoff, D. M., Narahari, S., Blank, M., Fuchs, J., Evans, C. H., Kahn, J. S., Johnson, M. O.  
2014; 30 (8): 730-737
- **Next: Text JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION**  
Kahn, J. S.  
2012; 307 (17): 1807-1808
- **Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.** *Science*  
Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S  
2010; 327 (5966): 697-701
- **Characteristics of Academic Physicians Associated With Patient Satisfaction** *AMERICAN JOURNAL OF MEDICAL QUALITY*  
Heidenreich, P., Shieh, L., Fassiotto, M., Kahn, J., Weinacker, A., Smith, R., Trockel, M., Shanafelt, T., Palaniappan, L.  
2019: 1062860619876344
- **Effect of a Lay HealthWorker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer A Randomized Clinical Trial** *JAMA ONCOLOGY*  
Patel, M. I., Sundaram, V., Desai, M., Periyakoil, V. S., Kahn, J. S., Bhattacharya, J., Asch, S. M., Milstein, A., Bundorf, M.  
2018; 4 (10): 1359–66
- **Disrupting end-of-life cancer care delivery: Results from the engagment of patients with advanced cancer trial.**  
Patel, M. I., Sundaram, V., Desai, M., Periyakoil, V. J., Kahn, J., Asch, S. M., Milstein, A., Bundorf, K.  
AMER SOC CLINICAL ONCOLOGY.2017
- **Effect of an Intensive Outpatient Program to Augment Primary Care for High-Need Veterans Affairs Patients A Randomized Clinical Trial** *JAMA INTERNAL MEDICINE*  
Zulman, D. M., Chee, C. P., Ezeji-Okoye, S. C., Shaw, J. G., Holmes, T. H., Kahn, J. S., Asch, S. M.  
2017; 177 (2): 166-175
- **Can lay health workers achieve the triple aim? Results from the Engagement of Patients with Advanced Cancer (EPAC) trial**  
Patel, M. I., Periyakoil, V., Bundorf, K., Thom, D., Milstein, A., Asch, S. M., Kahn, J.  
AMER SOC CLINICAL ONCOLOGY.2016
- **RANDOMIZED CONTROLLED EVALUATION OF AN INTENSIVE MANAGEMENT PATIENT ALIGNED CARE TEAM (IMPACT) FOR HIGH-NEED, HIGH-COST VETERANS AFFAIRS PATIENTS**  
Zulman, D. M., Chee, C., Ezeji-Okoye, S. C., Shaw, J. G., Kahn, J. S., Asch, S.  
SPRINGER.2015: S242–S243

- **Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*  
Nordell, A. D., McKenna, M., Borges, A. H., Duprez, D., Neuhaus, J., Neaton, J. D.  
2014; 3 (3)
- **Factors Associated with D-Dimer Levels in HIV-Infected Individuals** *PLOS ONE*  
Borges, A. H., O'Connor, J. L., Phillips, A. N., Baker, J. V., Vjecha, M. J., Losso, M. H., Klinker, H., Lopardo, G., Williams, I., Lundgren, J. D.  
2014; 9 (3)
- **Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care** *27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*  
Munoz, M. A., Liu, W., Delaney, J. A., Brown, E., Mugavero, M. J., Mathews, W. C., Napravnik, S., Willig, J. H., Eron, J. J., Hunt, P. W., Kahn, J. O., Saag, M. S., Kitahata, et al  
LIPPINCOTT WILLIAMS & WILKINS.2013: 254–60
- **Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy** *AIDS*  
Taiwo, B., Yanik, E. L., Napravnik, S., Ryscavage, P., Koletar, S. L., Moore, R., Mathews, W. C., Crane, H. M., Mayer, K., Zinski, A., Kahn, J. S., Eron, J. J.  
2013; 27 (10): 1593-1602
- **Hematologic, Hepatic, Renal, and Lipid Laboratory Monitoring After Initiation of Combination Antiretroviral Therapy in the United States, 2000-2010** *JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Yanik, E. L., Napravnik, S., Ryscavage, P., Eron, J. J., Koletar, S. L., Moore, R. D., Zinski, A., Cole, S. R., Hunt, P., Crane, H. M., Kahn, J., Mathews, W. C., Mayer, et al  
2013; 63 (2): 216-220
- **Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study** *PLOS ONE*  
Bjerk, S. M., Baker, J. V., Emery, S., Neuhaus, J., Angus, B., Gordin, F. M., Pett, S. L., Stephan, C., Kunisaki, K. M.  
2013; 8 (2)
- **Characterizing HIV Transmission Networks Across the United States** *CLINICAL INFECTIOUS DISEASES*  
Aldous, J. L., Pond, S. K., Poon, A., Jain, S., Qin, H., Kahn, J. S., Kitahata, M., Rodriguez, B., Dennis, A. M., Boswell, S. L., Haubrich, R., Smith, D. M.  
2012; 55 (8): 1135-1143
- **A Mentor Development Program for Clinical Translational Science Faculty Leads to Sustained, Improved Confidence in Mentoring Skills** *CTS-CLINICAL AND TRANSLATIONAL SCIENCE*  
Feldman, M. D., Steinauer, J. E., Khalili, M., Huang, L., Kahn, J. S., Lee, K. A., Creasman, J., Brown, J. S.  
2012; 5 (4): 362-367
- **A Cross-Sectional Study of Barriers to Personal Health Record Use among Patients Attending a Safety-Net Clinic** *PLOS ONE*  
Hilton, J. F., Barkoff, L., Chang, O., Halperin, L., Ratanawongsa, N., Sarkar, U., Leykin, Y., Munoz, R. F., Thom, D. H., Kahn, J. S.  
2012; 7 (2)
- **Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance** *SCIENTIFIC REPORTS*  
Supervie, V., Barrett, M., Kahn, J. S., Musuka, G., Moeti, T. L., Busang, L., Blower, S.  
2011; 1
- **A Randomized Noninferiority Trial of Standard Versus Enhanced Risk Reduction and Adherence Counseling for Individuals Receiving Post-Exposure Prophylaxis Following Sexual Exposures to HIV** *CLINICAL INFECTIOUS DISEASES*  
Roland, M. E., Neilands, T. B., Krone, M. R., Coates, T. J., Franses, K., Chesney, M. A., Kahn, J. S., Martin, J. N.  
2011; 53 (1): 76-83
- **Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load** *PLoS Med*  
Poon A, Frost S, Aldous J, Mathews W, Kitahata M, Rodriguez B, Saag M, Boswell S, Kahn J, Haubrich R  
2011; 6 (6): e21189
- **The effect of AIDS Clinical Trials Group Protocol 5164 on the time from *Pneumocystis jirovecii* pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation.** *Clin Infect Dis*  
Geng EH, Kahn JS, Chang OC, Hare CB, Christopoulos KA, Jones D, Petersen ML, Deeks SG, Havlir DV, Gandhi M  
2011; 53 (10): 1008-14

- **A Randomized Noninferiority Trial of Standard Versus Enhanced Risk Reduction and Adherence Counseling for Individuals Receiving Post-Exposure Prophylaxis Following Sexual Exposures to HIV** *Clin Infect Dis*  
Roland ME, Neilands TB, Krone MR, Coates TJ, Franses K, Chesney MA, Kahn JS, Martin JN.  
2011; 53 (1): 76-83
- **Mortality Among Antiretroviral-Eligible Patients in an Urban Public Clinic** *J Acquir Immune Defic Syndr*  
Dowdy DW, Geng EH, Christopoulos KA, Kahn JS, Hare CB, Wlodarczyk D, Havlir DV  
2011; 57 (4): 297-300
- **Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy?** *AIDS*  
Wagner BG, Kahn JS, Blower S  
2010; 13 (24): 775-6
- **Personal health records in a public hospital: experience at the HIV/AIDS clinic at San Francisco General Hospital.** *J Am Med Inform Assoc*  
Kahn JS, Hilton JF, Van Nunnery T, Leisure S, Bryant KM, Hare CB, Thom DH  
2010; 17 (2): 224-8
- **The potential roles of mHealth in developing economies: Can they be realized?** *Health Affairs*  
Kahn JG, Yang J, Kahn JS  
2010; 29 (2): 254-61
- **Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling** *OptAIDS Workshop 2009*  
Breban, R., Napravnik, S., Kahn, J., Blower, S.  
BIOMED CENTRAL LTD.2009
- **Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection** *16th Conference on Retroviruses and Opportunistic Infections (CROI)*  
Rodger, A. J., Fox, Z., Lundgren, J. D., Kuller, L. H., Boesecke, C., Gey, D., Skoutelis, A., Goetz, M. B., Phillips, A. N.  
OXFORD UNIV PRESS INC.2009: 973-83
- **What it takes: characteristics of the ideal personal health record** *Health Affairs*  
Kahn JS, Aulakh V, Bosworth A  
2009; 28 (2): 369-76
- **Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling.** *BMC Public Health*  
Breban R, Napravnik S, Kahn J, Blower S  
2009; 9 (Suppl 1): 11
- **Training the next generation of research mentors: the University of California, San Francisco, Clinical & Translational Science Institute Mentor Development Program.** *Clin Transl Sci*  
Feldman MD, Huang L, Guglielmo BJ, Jordan R, Kahn J, Creasman JM, Wiener-Kronish JP, Lee KA, Tehrani A, Yaffe K, Brown JS  
2009; 2 (3): 216-21
- **Mentoring early-career scientists for HIV research careers** *Am J Public Health*  
Kahn JS, Greenblatt RM  
2009; 99 (1 Suppl): S37-42
- **Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen** *AIDS*  
Fox, Z., Phillips, A., Cohen, C., Neuhaus, J., Baxter, J., Emery, S., Hirschel, B., Hullsiek, K. H., Stephan, C., Lundgren, J.  
2008; 22 (17): 2279-2289
- **Cohort profile: The Centers for AIDS Research Network of Integrated Clinical Systems** *INTERNATIONAL JOURNAL OF EPIDEMIOLOGY*  
Kitahata, M. M., Rodriguez, B., Haubrich, R., Boswell, S., Mathews, W. C., Lederman, M. M., Lober, W. B., Van Rompaey, S. E., Crane, H. M., Moore, R. D., Bertram, M., Kahn, J. O., Saag, et al  
2008; 37 (5): 948-955
- **Signposts along the NIH roadmap for reengineering clinical research - Lessons from the Clinical Research Networks Initiative** *ARCHIVES OF INTERNAL MEDICINE*  
Williams, R. L., Johnson, S. B., Greene, S. M., Larson, E. B., Green, L. A., Morris, A., Confer, D., Reaman, G., Madigan, R., Kahn, J.

2008; 168 (17): 1919-1925

• **Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study JOURNAL OF INFECTIOUS DISEASES**

Emery, S., Neuhaus, J. A., Phillips, A. N., Babiker, A., Cohen, C. J., Gatell, J. M., Girard, P., Grund, B., Law, M., Losso, M. H., Palfreeman, A., Wood, R. 2008; 197 (8): 1133-1144

• **Mentoring the next generation of HIV prevention researchers - A model mentoring program at the University of California San Francisco and Gladstone Institute of Immunology and Virology Center for AIDS research 1st National Scientific Meeting of the Social-and-Behavioral-Science-Research-Network**  
Kahn, J., Jarlais, C. D., Dobkin, L., Barrs, S. F., Greenblatt, R. M.

LIPPINCOTT WILLIAMS & WILKINS.2008: S5-S9

• **Signposts along the NIH roadmap for reengineering clinical research: lessons from the Clinical Research Networks initiative Arch Intern Med**

Williams RL, Johnson SB, Greene SM, Larson EB, Green LA, Morris A, Confer D, Reaman G, Madigan R, Kahn J; Principal Investigators of Clinical Research Networks Initiative

2008; 168 (17): 1919-25

• **Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo JOURNAL OF VIROLOGY**

Zimmerman, E. S., Sherman, M. P., Blackett, J. L., Neidleman, J. A., Kreis, C., Mundt, P., Williams, S. A., Warmerdam, M., Kahn, J., Hecht, F. M., Grant, R. M., de Noronha, C. M., Weyrich, et al  
2006; 80 (21): 10407-10418

• **Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol**

Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V  
2006; 80 (21): 10407-18

• **Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide. Proc Natl Acad Sci USA**

Wilson DP, Kahn J, Blower SM

2006; 103 (38): 14228-33

• **Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses**

Mulligan MJ, Russell ND, Celum C, Kahn J, Noonan E, Montefiori DC, Ferrari G, Weinhold KJ, Smith JM, Amara RR, Robinson HL; NIH/NIAID/DAIDS HIV Vaccine Trials Network.  
2006; 22 (7): 678-83

• **Seroconversion following nonoccupational postexposure prophylaxis against HIV 11th Conference on Retroviruses and Opportunistic Infections**

Roland, M. E., Neilands, T. B., Krone, M. R., Katz, M. H., Franses, K., Grant, R. M., Busch, M. P., Hecht, F. M., Shacklett, B. L., Kahn, J. O., Bamberger, J. D., Coates, T. J., Chesney, et al

OXFORD UNIV PRESS INC.2005: 1507-13

• **The antiretroviral rollout & drug resistant HIV in Africa: insights from empirical data & theoretical models. AIDS Res Hum Retroviruses**

Blower S, Bondine E, Kahn J, McFarland W  
2005; 19 (1): 1-14

• **Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART AIDS**

Martinez-Marino, B., Shibuski, S., Hecht, F. M., Kahn, J. O., Levy, J. A.  
2004; 18 (15): 1991-1999

• **Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States AIDS**

Pinkerton, S. D., Martin, J. N., Roland, M. E., Katz, M. H., Coates, T., Kahn, J. O.  
2004; 18 (15): 2065-2073

• **Immune activation set point during early FHV infection predicts subsequent CD4(+) T-cell changes independent of viral load BLOOD**

Deeks, S. G., Kitchen, C. M., Liu, L., Guo, H., Gascon, R., Narvaez, A. B., Hunt, P., Martin, J. N., Kahn, J. O., Levy, J., McGrath, M. S., Hecht, F. M.  
2004; 104 (4): 942-947

• **HIV RNA testing in the context of nonoccupational postexposure prophylaxis 7th Conference on Retroviruses and Opportunistic Infections**

Roland, M. E., Elbeik, T. A., Kahn, J. O., Bamberger, J. D., Coates, T. J., Krone, M. R., Katz, M. H., Busch, M. P., Martin, J. N.  
OXFORD UNIV PRESS INC.2004: 598-604

- **Higher CD4(+) T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection** *11th Conference on Retroviruses and Opportunistic Infections*  
Barbour, J. D., Hecht, F. M., Wrin, T., Segal, M. R., Ramstead, C. A., Liegler, T. J., Busch, M. P., Petropoulos, C. J., Hellmann, N. S., Kahn, J. O., Grant, R. M.  
OXFORD UNIV PRESS INC.2004: 251–56
- **Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior** *8th Conference on Retroviruses and Opportunistic Infections*  
Martin, J. N., Roland, M. E., Neilands, T. B., Krone, M. R., Bamberger, J. D., Kohn, R. P., Chesney, M. A., Franses, K., Kahn, J. O., Chesney, M. A., Franses, K., Kahn, J. O., Coates, et al  
LIPPINCOTT WILLIAMS & WILKINS.2004: 787–92
- **Primary HIV Infection.** *Current infectious disease reports*  
Hare, C. B., Kahn, J. O.  
2004; 6 (1): 65-71
- **Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus** *ARCHIVES OF INTERNAL MEDICINE*  
Pinkerton, S. D., Martin, J. N., Roland, M. E., Katz, M. H., Coates, T. J., Kahn, J. O.  
2004; 164 (1): 46-54
- **Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection** *AIDS*  
Altfeld, M., Addo, M. A., Rosenberg, E. S., Hecht, F. A., Lee, P. K., Vogel, M., Yu, X. G., Draenert, R., Johnston, M. N., Strick, D., Allen, T. A., Feeney, M. E., Kahn, et al  
2003; 17 (18): 2581-2591
- **Greater reversal of CD4(+) cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Smith, D. E., Kaufmann, G. R., Kahn, J. O., Hecht, F. M., Grey, P. A., Zaunders, J. J., Cunningham, P. H., Carr, A., Duncombe, C., Quan, D. C., Petersen, A., Cooper, D. A.  
2003; 19 (3): 189-199
- **Predicting the transmission of drug-resistant HIV: comparing theory with data** *LANCET INFECTIOUS DISEASES*  
Blower, S. M., Aschenbach, A. N., Kahn, J. O.  
2003; 3 (1): 10-11
- **Preventing hepatitis A and hepatitis B virus infections among men who have sex with men** *CLINICAL INFECTIOUS DISEASES*  
Kahn, J.  
2002; 35 (11): 1382-1387
- **Time trends in primary HIV-1 drug resistance among recently infected persons** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
Grant, R. M., Hecht, F. M., Warmerdam, M., Liu, L., Liegler, T., Petropoulos, C. J., Hellmann, N. S., Chesney, M., Busch, M. P., Kahn, J. O.  
2002; 288 (2): 181-188
- **Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Gascon, R. L., Narvaez, A. B., Zhang, R. Z., Kahn, J. O., Hecht, F. M., Herndier, B. G., McGrath, M. S.  
2002; 30 (2): 146-153
- **Use of laboratory tests and clinical symptoms for identification of primary HIV infection** *AIDS*  
Hecht, F. M., Busch, M. P., Rawal, B., Webb, M., Rosenberg, E., Swanson, M., Chesney, M., Anderson, J., Levy, J., Kahn, J. O.  
2002; 16 (8): 1119-1129
- **Development of WF10, a novel macrophage-regulating agent.** *Current opinion in investigational drugs*  
McGrath, M. S., Kahn, J. O., Herndier, B. G.  
2002; 3 (3): 365-373
- **Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: Identification and characterization of the source of exposure** *7th Conference on Retroviruses and Opportunistic Infections*  
Roland, M. E., Martin, J. N., Grant, R. M., Hellmann, N. S., Bamberger, J. D., Katz, M. H., Chesney, M., Franses, K., Coates, T. J., Kahn, J. O.  
UNIV CHICAGO PRESS.2001: 1608–12

- **Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Barditch-Crovo, P., Deeks, S. G., Collier, A., Safrin, S., Coakley, D. F., Miller, M., Kearney, B. P., Coleman, R. L., Lamy, P. D., Kahn, J. O., McGowan, I., Lietman, P. S.  
2001; 45 (10): 2733-2739
- **Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil)** *5th Conference on Retroviruses and Opportunistic Infections*  
Rousseau, F. S., Kahn, J. O., Thompson, M., Mildvan, D., Shepp, D., Sommadossi, J. P., Delehanty, J., Simpson, J. N., Wang, L. H., Quinn, J. B., Wakeford, C., van der Horst, C.  
OXFORD UNIV PRESS.2001: 507-13
- **Predicting the unpredictable: Transmission of drug-resistant HIV** *NATURE MEDICINE*  
Blower, S. M., Aschenbach, A. N., Gershengorn, H. B., Kahn, J. O.  
2001; 7 (9): 1016-1020
- **Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study** *6th Conference on Retroviruses and Opportunistic Infections*  
Kahn, J. O., Martin, J. N., Roland, M. E., Bamberger, J. D., Chesney, M., Chambers, D., Franses, K., Coates, T. J., Hatz, M. H.  
UNIV CHICAGO PRESS.2001: 707-14
- **Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Stranford, S. A., Ong, J. C., Martinez-Marino, B., Busch, M., Hecht, F. M., Kahn, J., Levy, J. A.  
2001; 98 (2): 597-602
- **Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection** *JOURNAL OF EXPERIMENTAL MEDICINE*  
Altfeld, M., Rosenberg, E. S., Shankarappa, R., Mukherjee, J. S., Hecht, F. M., Eldridge, R. L., Addo, M. M., Poon, S. H., Phillips, M. N., Robbins, G. K., Sax, P. E., Boswell, S., Kahn, et al  
2001; 193 (2): 169-180
- **Longitudinal analysis of T-cell receptor gene use by CD8(+) T cells in early human immunodeficiency virus infection in patients receiving highly active antiretroviral therapy** *BLOOD*  
Schito, A. M., Vittinghoff, E., Hecht, F. M., Elkins, M. K., Kahn, J. O., Levy, J. A., Oksenberg, J. R.  
2001; 97 (1): 214-220
- **Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.** *Proc Natl Acad Sci USA*  
Stranford SA, Ong JC, Martinez-Marino B, Busch M, Hecht FM, Kahn J, Levy JA.  
2001; 98 (2): 597-602
- **Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10<sup>6</sup>/L CD4 cell counts - A randomized controlled trial** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
Kahn, J. O., Cherng, D. W., Mayer, K., Murray, H., Lagakos, S.  
2000; 284 (17): 2193-2202
- **From the cell to the community: AIDS research in California** *WESTERN JOURNAL OF MEDICINE*  
Moss, N. E., Lemp, G., Bluthenthal, R., Goldsmith, M. A., Haubrich, R., Kahn, J. O.  
2000; 173 (2): 119-121
- **Current questions in HIV/AIDS research in California - Clinical sciences** *WESTERN JOURNAL OF MEDICINE*  
Moss, N. E., Lemp, G., Bluthenthal, R., Goldsmith, M. A., Haubrich, R., Kahn, J. O.  
2000; 173 (2): 121-124
- **Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
Davey, R. T., Murphy, R. L., Graziano, F. M., Boswell, S. L., Pavia, A. T., Cancio, M., Nadler, J. P., Chaitt, D. G., Dewar, R. L., Sahner, D. K., Duliege, A. M., Capra, W. B., Leong, et al  
2000; 284 (2): 183-189
- **Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA Quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor Monitor version 1.5** *JOURNAL OF CLINICAL MICROBIOLOGY*

Elbeik, T., Charlebois, E., Nassos, P., Kahn, J., Hecht, F. M., Yajko, D., Ng, V., Hadley, K.  
2000; 38 (3): 1113-1120

- **Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.** *J Infect Dis*

Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC Jr, McElrath MJ, Collier A, Plaege S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, et al  
2000; 182 (5): 1357-64

- **Efficacy and safety of adefovir dipivoxil with antiretroviral therapy - A randomized controlled trial** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*

Kahn, J., Lagakos, S., Wulfsohn, M., Cherng, D., Miller, M., Cherrington, J., Hardy, D., Beall, G., Cooper, R., Murphy, R., Basgoz, N., Ng, E., Deeks, et al  
1999; 282 (24): 2305-2312

- **Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination** *AIDS RESEARCH AND HUMAN RETROVIRUSES*

Locher, C. P., Grant, R. M., Collisson, E. A., Reyes-Teran, G., Elbeik, T., Kahn, J. O., Levy, J. A.  
1999; 15 (18): 1685-1689

- **Building and testing an effective HIV vaccine** *WESTERN JOURNAL OF MEDICINE*

Kahn, J.  
1999; 171 (5-6): 363-365

- **Initial treatment for HIV infection - When, why, and with what?** *5th Triennial Symposium on New Directions in Antiviral Chemotherapy*

Kahn, J. O.  
KLUWER ACADEMIC/PLENUM PUBL. 1999: 229-237

- **Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice** *VACCINE*

Sarin, P. S., Talmadge, J. E., Heseltine, P., Murcar, N., Gendelman, H. E., Coleman, R., Kelsey, L., Beckner, S., Winship, D., Kahn, J.  
1999; 17 (1): 64-71

- **Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice.** *Vaccine*

Sarin PS, Talmadge JE, Heseltine P, Murcar N, Gendelman HE, Coleman R, Kelsey L, Beckner S, Winship D, Kahn J.  
1999; 17 (1): 64-71

- **A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*

Henry, K., ERICE, A., Tierney, C., Balfour, H. H., Fischl, M. A., Kmack, A., Liou, S. H., Kenton, A., Hirsch, M. S., Phair, J., Martinez, A., Kahn, J. O.  
1998; 19 (4): 339-349

- **Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*

Deeks, S. G., Barditch-Crovo, P., Lietman, P. S., Hwang, F., Cundy, K. C., Rooney, J. F., Hellmann, N. S., Safrin, S., Kahn, J. O.  
1998; 42 (9): 2380-2384

- **Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors** *NEW ENGLAND JOURNAL OF MEDICINE*

Hecht, F. M., Grant, R. M., Petropoulos, C. J., Dillon, B., Chesney, M. A., Tian, H., Hellmann, N. S., Bandrapalli, N. I., Digilio, L., Branson, B., Kahn, J. O.  
1998; 339 (5): 307-311

- **Acute human immunodeficiency virus type 1 infection** *NEW ENGLAND JOURNAL OF MEDICINE*

Kahn, J. O., Walker, B. D.  
1998; 339 (1): 33-39

- **New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*

Janssen, R. S., Satten, G. A., Stramer, S. L., Rawal, B. D., O'Brien, T. R., Weiblen, B. J., Hecht, F. M., Jack, N., Cleghorn, F. R., Kahn, J. O., Chesney, M. A., Busch, M. P.  
1998; 280 (1): 42-48

- **Post-exposure prevention of HIV-1 infection** *ANTIVIRAL THERAPY*

Kahn, J. O.

1998; 3: 45-47

● **Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy.** *Nat Med*

Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, Rizzardi GP, Kahn J, Fox CH, Schnittman SM, Schwartz DH, Corey L, Fauci AS.  
1998; 4 (3): 341-5

● **Protease inhibitors do not increase the CD4+ cell count in HIV-uninfected individuals** *AIDS Res Hum Retroviruses*

Barker E, Kahn J, Fujimura S, Levy JA  
1998; 12 (8): 1117-8

● **Success and Sadness** *JAMA*

Kahn JO  
1998; 280 (1): 89

● **Risk behavior for HIV infection in participants in preventive HIV vaccine trials: A cautionary note** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*

Chesney, M. A., Chambers, D. B., Kahn, J. O.  
1997; 16 (4): 266-271

● **Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm<sup>3</sup>(3)** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY*

Spino, C., Kahn, J. O., Dolin, R., Phair, J. P.  
1997; 15 (5): 346-355

● **HIV-1 protease inhibitors - A review for clinicians** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*

Deeks, S. G., Smith, M., Holodniy, M., Kahn, J. O.  
1997; 277 (2): 145-153

● **Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines** *J Infect Dis*

Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, Clements ML, Duliege AM, Excler JL, Hioe C, Kahn J, McElrath MJ, Sharpe S, Sinangil F, Steimer K, Walker MC, Wassef N, Xu S  
1997; 175 (4): 764-74

● **Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm<sup>3</sup>** *J Acquir Immune Defic Syndr*

Spino C, Kahn JO; Dolin R; Phair JP  
1997; 15: 346-55

● **Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy** *JOURNAL OF INFECTIOUS DISEASES*

Welles, S. L., Jackson, J. B., YENLIEBERMAN, B., Demeter, L., JAPOUR, A. J., Smeaton, L. M., JOHNSON, V. A., Kuritzkes, D. R., DAQUILA, R. T., REICHELDERFER, P. A., Richman, D. D., REICHMAN, R., Fischl, et al  
1996; 174 (4): 696-703

● **Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection** *JOURNAL OF INFECTIOUS DISEASES*

COOMBS, R. W., Welles, S. L., Hooper, C., REICHELDERFER, P. S., DAQUILA, R. T., JAPOUR, A. J., JOHNSON, V. A., Kuritzkes, D. R., Richman, D. D., Kwok, S., Todd, J., Jackson, J. B., DeGruttola, et al  
1996; 174 (4): 704-712

● **Phase 1 study of combination therapy with L-697,661 and zidovudine** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY*

Schooley, R. T., Campbell, T. B., Kuritzkes, D. R., Blaschke, T., Stein, D. S., Rosandich, M. E., Phair, J., Pottage, J. C., Messari, F., Collier, A., Kahn, J., Ray, G., Curtis, et al  
1996; 12 (4): 363-370

● **The clinical use of didanosine** *4th Triennial Symposium on New Directions in Antiviral Chemotherapy*

Kahn, J.  
PLENUM PRESS DIV PLENUM PUBLISHING CORP.1996: 245-256

● **Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor: the effects of zidovudine** *J Clinical Pharm*

Aweeka FT, Kwong M; Mak M; al-Uzri A; Affrime M; Cutler D; Kahn J; Gambertoglio JG

1996; 36 (1): 107-113

● **Phase 1 study of combination therapy with L-697, 661 and zidovudine** *J Acquir Immune Defic Syndr*

Schooley RT, Campbell TB; Kuritzkes DR; Blaschke T; Stein DS; Rosandich ME; Phair J; Pottage JC; Messari F; Collier A; Kahn, J for the ACTG 184 Protocol Team  
1996; 12: 363-70

● **Patterns of opportunistic infections in patients with HIV infection** *J Acquir Immune Defic Syndr*

Finkelstein DM, Williams PL, Molenberghs G, Feinberg J, Powderly WG, Kahn J, Dolin R, Cotton D  
1996; 12: 38-45

● **WEEKLY ORAL ETOPOSIDE IN PATIENTS WITH KAPOSI-SARCOMA ASSOCIATED WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A PHASE-I MULTICENTER TRIAL OF THE AIDS CLINICAL-TRIALS GROUP** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY*

Paredes, J., Kahn, J. O., Tong, W. P., Feldstein, M. L., Lin, S. L., Bennett, J. M., METROKA, C. E., Ratner, L., Krown, S. E.  
1995; 9 (2): 138-144

● **PREVALENCE AND CLINICAL-SIGNIFICANCE OF ZIDOVUDINE RESISTANCE MUTATIONS IN HUMAN-IMMUNODEFICIENCY-VIRUS ISOLATED FROM PATIENTS AFTER LONG-TERM ZIDOVUDINE TREATMENT** *JOURNAL OF INFECTIOUS DISEASES*

JAPOUR, A. J., Welles, S., DAQUILA, R. T., JOHNSON, V. A., Richman, D. D., COOMBS, R. W., REICHELDERFER, P. S., Kahn, J. O., CRUMPACKER, C. S., Kuritzkes, D. R.  
1995; 171 (5): 1172-1179

● **CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OBSERVATIONS RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-I INFECTION IN A VOLUNTEER IN AN HIV-1 VACCINE CLINICAL-TRIAL** *JOURNAL OF INFECTIOUS DISEASES*

Kahn, J. O., Steimer, K. S., Baenziger, J., Duliege, A. M., Feinberg, M., Elbeik, T., Chesney, M., Murcar, N., Chernoff, D., Sinangil, F.  
1995; 171 (5): 1343-1347

● **ZIDOVUDINE RESISTANCE AND HIV-1 DISEASE PROGRESSION DURING ANTIRETROVIRAL THERAPY** *ANNALS OF INTERNAL MEDICINE*

DAQUILA, R. T., JOHNSON, V. A., Welles, S. L., JAPOUR, A. J., Kuritzkes, D. R., DeGruttola, V., REICHELDERFER, P. S., COOMBS, R. W., CRUMPACKER, C. S., Kahn, J. O., Richman, D. D.  
1995; 122 (6): 401-408

● **HIV CARE - A CHANGING HEALTH-CARE SYSTEM** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY*

Kahn, J. O., Smith, M. D.  
1995; 8: S1-S3

● **HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.** *Cell Mol Biol*

Sarin PS, Mora CA, Naylor PH, Markham R, Schwartz D, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A, et al.  
1995; 41 (3): 401-7

● **CLINICAL AND IMMUNOLOGICAL RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE 1(SF2) GP120 SUBUNIT VACCINE COMBINED WITH MF59 ADJUVANT WITH OR WITHOUT MURAMYL TRIPÉPTIDE DIPALMITOYL PHOSPHATIDYLETHANOLAMINE IN NON-HIV-INFECTED HUMAN VOLUNTEERS** *JOURNAL OF INFECTIOUS DISEASES*

Kahn, J. O., Sinangil, F., Baenziger, J., Murcar, N., Wynne, D., Coleman, R. L., Steimer, K. S., Dekker, C. L., Chernoff, D.  
1994; 170 (5): 1288-1291

● **SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GLQ223 IN PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX ANTIMICROBIAL AGENTS AND CHEMOTHERAPY**

Kahn, J. O., Gorelick, K. J., Gatti, G., ARRI, C. J., Lifson, J. D., Gambertoglio, J. G., Bostrom, A., WILLIAMS, R.  
1994; 38 (2): 260-267

● **URIC-ACID AND DIDANOSINE COMPLIANCE IN AIDS CLINICAL-TRIALS - AN ANALYSIS OF AIDS CLINICAL-TRIALS GROUP PROTOCOL-116A AND PROTOCOL-116B/117** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*

Richardson, D., Liou, S. H., Kahn, J. O.  
1993; 6 (11): 1212-1223

● **NEUROLOGICAL REACTIONS IN HIV-INFECTED PATIENTS TREATED WITH TRICHOSANTHIN** *NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY*

Garcia, P. A., Bredesen, D. E., Vinters, H. V., VONEINSIEDEL, R. G., Williams, R. L., Kahn, J. O., Byers, V. S., Levin, A. S., WAITES, L. A., Messing, R. O.

1993; 19 (5): 402-405

● **Vaccines directed against HIV: preventive and therapeutic strategies. AIDS clinical review**

Kahn, J. O., Birx, D. L.

1993: 213-238

● **A CONTROLLED TRIAL COMPARING CONTINUED ZIDOVUDINE WITH DIDANOSINE IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION NEW ENGLAND JOURNAL OF MEDICINE**

Kahn, J. O., Lagakos, S. W., Richman, D. D., Cross, A., Pettinelli, C., Liou, S. H., Brown, M., Volberding, P. A., CRUMPACKER, C. S., Beall, G., Sacks, H. S., Merigan, T. C., BELTANGADY, et al

1992; 327 (9): 581-587

● **A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects. AIDS research and human retroviruses**

Kahn, J. O., Stites, D. P., Scillian, J., Murcar, N., Stryker, R., Volberding, P. A., Naylor, P. H., Goldstein, A. L., Sarin, P. S., Simmon, V. F.

1992; 8 (8): 1321-1325

● **A PHASE-I STUDY OF HGP-30, A 30 AMINO-ACID SUBUNIT OF THE HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) P17 SYNTHETIC PEPTIDE ANALOG SUBUNIT VACCINE IN SERONEGATIVE SUBJECTS INTERNATIONAL CONF ON ADVANCES IN AIDS VACCINE DEVELOPMENT / 4TH ANNUAL MEETING OF THE NATIONAL COOPERATIVE VACCINE DEVELOPMENT GROUP FOR AIDS**

Kahn, J. O., Stites, D. P., Scillian, J., Murcar, N., Stryker, R., Volberding, P. A., Naylor, P. H., Goldstein, A. L., Sarin, P. S., Simmon, V. F., Wang, S. S., Heseltine, P.

MARY ANN LIEBERT INC PUBL. 1992: 1321-25

● **CD4 IMMUNOADEHSINS IN ANTI-HIV THERAPY - NEW DEVELOPMENTS CONF ON BISPECIFIC ANTIBODIES AND TARGETED CELLULAR CYTOTOXICITY**

Chamow, S. M., Duliege, A. M., Ammann, A., Kahn, J. O., Allen, J. D., Eichberg, J. W., Byrn, R. A., Capon, D. J., WARD, R. H., Ashkenazi, A.

JOHN WILEY & SONS INC. 1992: 69-72

● **AIDS-associated Kaposi's sarcoma. AIDS clinical review**

Kahn, J. O., Northfelt, D. W., Miles, S. A.

1992: 261-280

● **PHARMACOKINETICS OF GLQ223 IN RATS, MONKEYS, AND PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX ANTIMICROBIAL AGENTS AND CHEMOTHERAPY**

Gatti, G., Kahn, J. O., Lifson, J., WILLIAMS, R., Turin, L., Volberding, P. A., Gambertoglio, J. G.

1991; 35 (12): 2531-2537

● **PHASE-1 STUDY OF RECOMBINANT HUMAN CD4-IMMUNOGLOBULIN-G THERAPY OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX ANTIMICROBIAL AGENTS AND CHEMOTHERAPY**

HODGES, T. L., Kahn, J. O., Kaplan, L. D., Groopman, J. E., Volberding, P. A., AMMAN, A. J., ARRI, C. J., BOUVIER, L. M., Mordenti, J., Izu, A. E., Allan, J. D.

1991; 35 (12): 2580-2586

● **Chemotherapy for AIDS-associated Kaposi's sarcoma. Oncology (Williston Park, N.Y.)**

Kahn, J., Northfelt, D., Volberding, P.

1991; 5 (10): 57-63

● **CLINICAL AND VIROLOGICAL EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS RECEIVING CHEMOTHERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED NON-HODGKINS-LYMPHOMA - RESULTS OF A RANDOMIZED TRIAL JOURNAL OF CLINICAL ONCOLOGY**

Kaplan, L. D., Kahn, J. O., Crowe, S., Northfelt, D., Neville, P., Grossberg, H., Abrams, D. I., Tracey, J., Mills, J., Volberding, P. A.

1991; 9 (6): 929-940

● **TREATMENT OF AIDS-RELATED KAPOSI-SARCOMA HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA**

Northfelt, D. W., Kahn, J. O., Volberding, P. A.

1991; 5 (2): 297-310

● **CRYOTHERAPY FOR CUTANEOUS KAPOSI-SARCOMA (KS) ASSOCIATED WITH ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME (AIDS) - A PHASE-II TRIAL JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY**

Tappero, J. W., Berger, T. G., Kaplan, L. D., Volberding, P. A., Kahn, J. O.

1991; 4 (9): 839-846

- **THE SAFETY AND PHARMACOKINETICS OF GLQ223 IN SUBJECTS WITH AIDS AND AIDS-RELATED COMPLEX - A PHASE-I STUDY AIDS**  
Kahn, J. O., Kaplan, L. D., Gambertoglio, J. G., Bredesen, D., ARRI, C. J., Turin, L., KIBORT, T., Williams, R. L., Lifson, J. D., Volberding, P. A.  
1990; 4 (12): 1197-1204
- **THE SAFETY AND PHARMACOKINETICS OF RECOMBINANT SOLUBLE CD4 (RCD4) IN SUBJECTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME (AIDS) AND AIDS-RELATED COMPLEX - A PHASE-1 STUDY ANNALS OF INTERNAL MEDICINE**  
Kahn, J. O., Allan, J. D., HODGES, T. L., Kaplan, L. D., ARRI, C. J., FITCH, H. F., Izu, A. E., Mordini, J., SHERWIN, S. A., Groopman, J. E., Volberding, P. A.  
1990; 112 (4): 254-261
- **AIDS-associated Kaposi's sarcoma. AIDS clinical review**  
Kahn, J. O.  
1990: 115-128
- **INTRALESIONAL RECOMBINANT TUMOR NECROSIS FACTOR-ALPHA FOR AIDS-ASSOCIATED KAPOSI'S SARCOMA - A RANDOMIZED, DOUBLE-BLIND TRIAL JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES**  
Kahn, J. O., Kaplan, L. D., Volberding, P. A., Ziegler, J. L., Crowe, S., SAKS, S. R., Abrams, D. I.  
1989; 2 (3): 217-223